Erik Chi-Lik Ng
Algemeen Directeur bij Xing Ling International Pte Ltd.
Oorsprong van het eerstegraads netwerk van Erik Chi-Lik Ng
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.
17
| Subsidiary | Pharmaceuticals: Major | 17 |
Xing Ling International Pte Ltd.
Xing Ling International Pte Ltd. Medical DistributorsDistribution Services Xing Ling International Pte Ltd. distributes Chinese and Western medicine. The company was founded in 2005 and is headquartered in Singapore.
2
| Private Company | Medical Distributors | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Erik Chi-Lik Ng via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Investment Banks/Brokers | Analyst-Equity | |
CTI BIOPHARMA CORP. | Pharmaceuticals: Major | Director/Board Member | |
Rochester Christian University | College/University | Doctorate Degree | |
IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Viridos, Inc.
Viridos, Inc. Miscellaneous Commercial ServicesCommercial Services Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA. | Miscellaneous Commercial Services | Director/Board Member | |
REALM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
AILERON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Director/Board Member | |
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | Miscellaneous Commercial Services | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
National University of Singapore | College/University | Undergraduate Degree | |
Boston University | College/University | Undergraduate Degree | |
NEA Management Co. LLC
NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
Susquehanna University | College/University | Undergraduate Degree | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
INOVIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Genedata AG
Genedata AG Packaged SoftwareTechnology Services Genedata AG transforms data into intelligence with a portfolio of advanced software solutions. Its products include biologics, screener, expressionist, profiler, analyst, phylosospher, selector, imagence and bioprocess. The firm offers data analysis, information technology, training, software, development and hosting services to pharmaceutical, agrochemical, Industrial biotechnology companies and non-profit research organizations. The company was founded by Othmar Pfannes in 1997 and is headquartered in Basel, Switzerland. | Packaged Software | Chairman | |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Private Equity Investor | |
University of Warwick | College/University | Masters Business Admin | |
University of Regensburg | College/University | Doctorate Degree | |
SYMETIS SA | Biotechnology | Director/Board Member | |
Novartis Bioventure Fund
Novartis Bioventure Fund Investment ManagersFinance Novartis Bioventure Fund focuses on companies operating in the field of life science technology. The geographical focus includes the US, Canada, UK and Switzerland. The fund invests in biotechnology, pharmaceuticals and medical device products. It invests in all stages of financing and also invests in mezzanine transactions. | Investment Managers | President | |
TIGER AIRWAYS HOLDINGS LIMITED | Airlines | President | |
International Society for Biological Therapy of Cancer
International Society for Biological Therapy of Cancer Miscellaneous Commercial ServicesCommercial Services The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI. | Miscellaneous Commercial Services | President | |
New Enterprise Associates (India) LLC | Corporate Officer/Principal | ||
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
Columbia University Medical Center | College/University | Corporate Officer/Principal | |
Weill Cornell Medical College | College/University | Doctorate Degree | |
ESSA PHARMA INC. | Pharmaceuticals: Major | Chief Executive Officer | |
The Johns Hopkins University School of Medicine | College/University | Doctorate Degree | |
Zanvyl Krieger School of Arts & Sciences | College/University | Undergraduate Degree | |
University of Toronto Faculty of Medicine | College/University | Doctorate Degree | |
CNS PHARPAR | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Founder | |
AFFLUENT MEDICAL | Medical Specialties | Director/Board Member | |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Biotechnology | Chairman | |
Pierian Biosciences LLC
Pierian Biosciences LLC Medical/Nursing ServicesHealth Services Pierian Biosciences LLC operates as a diagnostic development and laboratory service company. It offers ChemoINTEL, a functional multi-parametric chemosensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumor cells; and ImmunoINTEL, a flow cytometry-based platform delivering phenotypic characterization and quantitative functional interrogation of tumor and immune populations within a tumor sample and relevant tissues. The company is headquartered in Franklin, TN. | Medical/Nursing Services | Director/Board Member | |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | Medical Specialties | Director/Board Member | |
Versameb AG
Versameb AG Miscellaneous Commercial ServicesCommercial Services Versameb AG operates as an preclinical-stage biopharmaceutical company. The company was founded by Friedrich Metzger, Roger Meier and Urs Breitenstein in 2018 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman |
Statistieken
Internationaal
Verenigde Staten | 30 |
Zwitserland | 12 |
Singapore | 4 |
Verenigd Koninkrijk | 3 |
Canada | 3 |
Sectoraal
Health Technology | 24 |
Consumer Services | 12 |
Commercial Services | 7 |
Finance | 6 |
Electronic Technology | 2 |
Operationeel
Corporate Officer/Principal | 57 |
Director/Board Member | 55 |
President | 14 |
Independent Dir/Board Member | 12 |
Investor Relations Contact | 10 |
Sterkste connecties
Insiders | |
---|---|
David Parkinson | 31 |
Reinhard Ambros | 20 |
John Kelly | 16 |
Rachel King | 14 |
Robert E. Pelzer | 12 |
Julian Lionel Sandt | 10 |
Vanessa Broadhurst | 9 |
Jean-Jacques Charhon | 9 |
James Caruso | 8 |
Sandra Silberman | 8 |
A. Schobel | 7 |
Patrick Gan | 7 |
Lukas Scheibler | 6 |
John D. Menditto | 6 |
Arun Nadiga | 5 |
- Beurs
- Insiders
- Erik Chi-Lik Ng
- Bedrijfsconnecties